The Society for Biomaterials has recognized an Indian-American biomedical engineer with its 2025 Technology Innovation and Development Award.
Ashutosh Chilkoti, the Alan L. Kaganov distinguished professor of biomedical engineering at Duke University, has received the award for his contributions to developing biomaterials that improve medical and surgical treatments.
Chilkoti’s research focuses on biomolecular engineering and biointerface science, leading to advancements in protein-resistant polymer coatings, ultrasensitive diagnostic devices, and chromatography-free methods for purifying protein drugs and viral vectors. His recent work explores the role of biological condensates in cellular electrochemistry.
His innovations have led to the creation of multiple startups, including PhaseBio Pharmaceutics, Sentilus, Gateway Bio, Isolere Bio and InSoma Bio. PhaseBio Pharmaceuticals, which became publicly traded in 2018, recently completed a Phase II clinical trial for a peptide drug targeting type 2 diabetes.
Beyond his research, Chilkoti served as chair of Duke’s biomedical engineering department from 2016 to 2022, overseeing its growth and rising global reputation.
“It’s a great honor to be recognized by the Society for Biomaterials, and I want to thank all my lab members, past and current, who did the work that led to this award,” Chilkoti said.
Chilkoti earned his Bachelor of Technology degree in chemical engineering from the Indian Institute of Technology (IIT) Delhi, and graduate studies at the University of Washington, where he received his Ph.D. in chemical engineering. Following this, he conducted post-doctoral research at the University's Center for Bioengineering.
The Society for Biomaterials is dedicated to advancing biomedical materials research and development. The 2025 award ceremony will take place on April 9 during the organization’s annual meeting in Chicago.
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login